Literature DB >> 26534876

Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.

Ronald Rivera1, Alexandra Banks2, America Casillas-Lopez3, Afshin Rashtian4, Bernie Lewinsky2, Pulin Sheth3, Linda Hovannesian-Larsen3, David Brousseau2, Geeta Iyengar5, Dennis R Holmes2.   

Abstract

Multiple long-term studies have demonstrated a propensity for breast cancer recurrences to develop near the site of the original breast cancer. Recognition of this local recurrence pattern laid the foundation for the development of accelerated partial breast irradiation (APBI) approaches designed to limit the radiation treatment field to the site of the malignancy. However, there is a paucity of data regarding the efficacy of APBI in general, and intraoperative radiotherapy (IORT), in particular, for the management of ductal carcinoma in situ (DCIS). As a result, use of APBI, remains controversial. A prospective nonrandomized trial was designed to determine if patients with pure DCIS considered eligible for concurrent IORT based on preoperative mammography and contrast-enhanced magnetic resonance imaging (CE-MRI) could be successfully treated using IORT with minimal need for additional therapy due to inadequate surgical margins or excessive tumor size. Between November 2007 and June 2014, 35 women underwent bilateral digital mammography and bilateral breast CE-MRI prior to selection for IORT. Patients were deemed eligible for IORT if their lesion was ≤4 cm in maximal diameter on both digital mammography and CE-MRI, pure DCIS on minimally invasive breast biopsy or wide local excision, and considered resectable with clear surgical margins using breast-conserving surgery (BCS). Postoperatively, the DCIS lesion size determined by imaging was compared with lesion size and surgical margin status obtained from the surgical pathology specimen. Thirty-five patients completed IORT. Median patient age was 57 years (range 42-79 years) and median histologic lesion size was 15.6 mm (2-40 mm). No invasive cancer was identified. In more than half of the patients in our study (57.1%), MRI failed to detect a corresponding lesion. Nonetheless, 30 patients met criteria for negative margins (i.e., margins ≥2 mm) whereas five patients had positive margins (<2 mm). Two of the five patients with positive margins underwent mastectomy due to extensive imaging-occult DCIS. Three of the five patients with positive margins underwent successful re-excision at a subsequent operation prior to subsequent whole breast irradiation. A total of 14.3% (5/35) of patients required some form of additional therapy. At 36 months median follow-up (range of 2-83 months, average 42 months), only two patients experienced local recurrences of cancer (DCIS only), yielding a 5.7% local recurrence rate. No deaths or distant recurrences were observed. Imaging-occult DCIS is a challenge for IORT, as it is for all forms of breast-conserving therapy. Nonetheless, 91.4% of patients with DCIS were successfully managed with BCS and IORT alone, with relatively few patients requiring additional therapy.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  IORT; breast cancer; ductal carcinoma in situ; intraoperative radiotherapy; partial breast irradiation

Mesh:

Substances:

Year:  2015        PMID: 26534876     DOI: 10.1111/tbj.12516

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  6 in total

Review 1.  Brachytherapy in the treatment of breast cancer.

Authors:  Xinna Deng; Haijiang Wu; Fei Gao; Ye Su; Qingxia Li; Shuzhen Liu; Jianhui Cai
Journal:  Int J Clin Oncol       Date:  2017-06-29       Impact factor: 3.402

2.  Intraoperative radiotherapy (IORT) versus whole-breast external beam radiotherapy (EBRT) in early stage breast cancer: results from SEER database.

Authors:  Juan Lei; Yi Wang; Zhuofei Bi; Shengneng Xue; Bing Ou; Kan Liu
Journal:  Jpn J Radiol       Date:  2019-11-05       Impact factor: 2.374

Review 3.  Intraoperative Radiotherapy for Breast Cancer.

Authors:  Eleanor E R Harris; William Small
Journal:  Front Oncol       Date:  2017-12-22       Impact factor: 6.244

4.  RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer.

Authors:  Chao Xiao; Yupeng Wang; Miao Zheng; Jian Chen; Guohe Song; Zhijie Zhou; Chongzhi Zhou; Xing Sun; Lin Zhong; Erxun Ding; Yi Zhang; Liu Yang; Gang Wu; Shifeng Xu; Hong Zhang; Xiaoliang Wang
Journal:  Cancer Sci       Date:  2018-03-10       Impact factor: 6.716

5.  A Single-Institution Experience in the Preoperative Selection of DCIS Patients for IORT using the ASTRO Consensus Guidelines.

Authors:  Christine Chin; Sitara Hirji; Maika Onishi; Richard Ha; Bret Taback; David P Horowitz; Eileen P Connolly
Journal:  Adv Radiat Oncol       Date:  2018-11-20

6.  Single institute experience of intraoperative radiation therapy in early-stage breast cancer.

Authors:  Mau-Shin Chi; Hui-Ling Ko; Chang-Cheng Chen; Chung-Hsien Hsu; Liang-Kuang Chen; Fiona Tsui-Fen Cheng
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.